Kerecis, the company pioneering the use of fish skin and fatty acids in cellular therapy, tissue regeneration and protection, has received authorization from the FDA to market Kerecis Omega3 SurgiBind.
The product, which is available now in the US, is an implantable fish-skin graft for use in plastic and reconstructive surgery. It is indicated for implantation to reinforce soft tissue where weakness exists, in patients requiring soft tissue repair, or reinforcement in plastic or reconstructive surgery.
Vascular surgeon Dr. Hector Crespo Soto of the Sanger Heart and Vascular Institute of Atrium Health is the first physician to use SurgiBind commercially outside of a study, Kerecis notes in a media release.
“I used the product in a ray amputation surgery, and I was pleased with the outcome. There were no post-op complications; the incision stayed closed and healed quickly,” he says. “The Kerecis product complements surgical procedures, provides a bacterial barrier and reinforces the body’s healing mechanism.”
Kerecis Omega3 SurgiBind helps practitioners better manage the risk of complications and improve outcomes. The fish-skin technology provides rapid incorporation and cell ingrowth, accelerated neovascularization and faster wound closure, all of which speed full tissue remodeling. Potential applications include reinforcement of soft tissues in abdominal incisions, surgical flaps and hip arthroplasty.
“This new product re-enforces our entry into the surgical market and demonstrates that the benefits of our technology extend beyond treating severe wounds and preventing amputations,” says Kerecis founder and CEO, Fertram Sigurjonsson, in the release.
[Source(s): Kerecis, Business Wire]
